Danimer Scientific (DNMR) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue declined 21% year-over-year, mainly due to lower PHA and PLA sales from customer reallocations and reduced demand.

• Interim CEO emphasized the company's unique position in biodegradable materials and strong customer relationships, supporting long-term growth.

• Cost reduction efforts, including headcount rationalization, helped decrease adjusted gross loss, though inflationary pressures and unfavorable cost absorption partially offset gains.

• Leadership transition is ongoing, with a national search firm retained for a permanent CEO.

• Substantial doubt exists about the ability to continue as a going concern due to negative cash flows and limited liquidity.

Financial highlights

• Q3 2024 revenue was $8.6M, down from $10.9M in Q3 2023; nine-month revenue was $26.5M, down from $35.7M year-over-year.

• Q3 2024 net loss was $21.8M, improved from $40.2M in Q3 2023, aided by a $6.8M gain on loan extinguishment.

• Adjusted EBITDA loss improved to $8.9M from $9.3M in Q3 2023.

• Gross loss for Q3 2024 was $7.3M, similar to the prior year's $7.7M gross loss; adjusted gross loss improved to $2.3M from $2.6M.

• Cash and cash equivalents at quarter end were $22.2M; total debt was $381.9M.

Outlook and guidance

• Full-year 2024 adjusted EBITDA expected between -$34.4M and -$34.9M, within prior guidance.

• Q4 adjusted EBITDA projected between -$7M and -$7.5M.

• Full-year capital expenditures forecasted at $8M-$9M.

• No year-end 2024 liquidity outlook provided due to ongoing liquidity management efforts.

• Anticipates significant near-term revenue growth in 2025 from new customer awards, but these revenues are uncontracted and liquidity is insufficient to sustain operations until then.